Key U.S. Patent Expiry for Trametinib
Trametinib (brand name Mekinist), developed by Novartis, has its primary U.S. composition-of-matter patent (US 7,250,402) expiring on July 6, 2026. Pediatric exclusivity adds six months, pushing full market exclusivity to January 6, 2027.[1][2]
When Do Other Major Patents Expire?
Several method-of-use and formulation patents extend protection beyond 2026:
- US 8,501,759 (dosing regimens): Expires February 11, 2031.
- US 8,829,011 (combination therapies): Expires March 25, 2032.
- US 9,974,729 (specific formulations): Expires December 12, 2033.[1][3]
These later expiries block generics until resolved via litigation or settlements.
Status of Generic Entry and Challenges
No generics are approved yet. Multiple ANDA filings (e.g., from MSN, Sun Pharma) face Paragraph IV challenges, triggering Hatch-Waxman litigation. FDA tentative approvals exist, but launch is delayed until at least 2027, with some possibly held to 2031+ due to secondary patents.[1][4]
Expiry Timeline in Europe and Elsewhere
In Europe, the key patent (EP 1412358) expires May 12, 2026, with supplementary protection to January 25, 2028. Japan expiry is February 27, 2028.[1][5]
Impact on Pricing and Biosimilars
Post-2026 expiry of the main patent could cut U.S. prices 80-90%, but secondary patents maintain high costs ($15,000+/month) until 2030s. Trametinib isn't biologic, so generics—not biosimilars—await entry.[1][6]
Sources
[1]: DrugPatentWatch.com - Trametinib Patents
[2]: FDA Orange Book - Mekinist
[3]: USPTO Patent Database
[4]: FDA Paragraph IV Patent Certifications
[5]: EMA Patent Register
[6]: IQVIA Market Data